These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 31339961

  • 1. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
    Huoponen S, Aaltonen KJ, Viikinkoski J, Rutanen J, Relas H, Taimen K, Puolakka K, Nordström D, Blom M.
    PLoS One; 2019; 14(7):e0220142. PubMed ID: 31339961
    [Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Muszbek N, Proudfoot C, Fournier M, Chen CI, Kuznik A, Kiss Z, Gal P, Michaud K.
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A, Baerwald C, Zeidler H, Krüger K, Neubauer AS, Dupont D, Merkesdal S.
    Clin Exp Rheumatol; 2013 Nov; 31(3):400-8. PubMed ID: 23464803
    [Abstract] [Full Text] [Related]

  • 4. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S, Everett CC, Naraghi K, Davies C, Dawkins B, Hulme C, McCabe C, Pavitt S, Emery P, Sharples L, Buch MH.
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Bae SC.
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ.
    J Med Econ; 2012 Nov; 15(2):340-51. PubMed ID: 22168785
    [Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X, French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries.
    BMJ; 2019 Jan 24; 364():l67. PubMed ID: 30679233
    [Abstract] [Full Text] [Related]

  • 8. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting.
    Hallinen TA, Soini EJ, Eklund K, Puolakka K.
    Rheumatology (Oxford); 2010 Apr 24; 49(4):767-77. PubMed ID: 20100793
    [Abstract] [Full Text] [Related]

  • 9. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.
    JAMA Intern Med; 2017 Nov 01; 177(11):1605-1612. PubMed ID: 28975211
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.
    Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE, Hendrikx J, Jansen TL, Westhovens R, van de Laar MA, van Riel PL.
    Arthritis Res Ther; 2015 May 22; 17(1):134. PubMed ID: 25997746
    [Abstract] [Full Text] [Related]

  • 11. Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis.
    Lopatina E, Marshall DA, Coupal L, Le Lorier J, Choquette D.
    Curr Med Res Opin; 2021 Jan 22; 37(1):157-166. PubMed ID: 33136462
    [Abstract] [Full Text] [Related]

  • 12. Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting.
    Schmier J, Ogden K, Nickman N, Halpern MT, Cifaldi M, Ganguli A, Bao Y, Garg V.
    Clin Ther; 2017 Aug 22; 39(8):1600-1617. PubMed ID: 28716293
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
    Neubauer AS, Minartz C, Herrmann KH, Baerwald CGO.
    Clin Exp Rheumatol; 2018 Aug 22; 36(3):448-454. PubMed ID: 29303709
    [Abstract] [Full Text] [Related]

  • 14. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y, Trivedi D, Maclean R, Rosenblatt L.
    J Med Econ; 2010 Mar 22; 13(1):33-41. PubMed ID: 20001596
    [Abstract] [Full Text] [Related]

  • 15. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ.
    J Med Econ; 2015 May 22; 18(5):376-89. PubMed ID: 25530318
    [Abstract] [Full Text] [Related]

  • 16. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
    Gülfe A, Wallman JK, Kristensen LE.
    Arthritis Res Ther; 2016 Feb 19; 18():51. PubMed ID: 26892115
    [Abstract] [Full Text] [Related]

  • 17. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, Houvenagel E, Flipo RM.
    Int J Rheum Dis; 2016 Nov 19; 19(11):1093-1102. PubMed ID: 27018857
    [Abstract] [Full Text] [Related]

  • 18. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
    Grøn KL, Glintborg B, Nørgaard M, Mehnert F, Østergaard M, Dreyer L, Krogh NS, Hetland ML.
    Rheumatology (Oxford); 2020 Aug 01; 59(8):1949-1956. PubMed ID: 31764977
    [Abstract] [Full Text] [Related]

  • 19. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.
    Alemao E, Johal S, Al MJ, Rutten-van Mölken M.
    Value Health; 2018 Feb 01; 21(2):193-202. PubMed ID: 29477401
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V.
    J Med Econ; 2017 Jul 01; 20(7):703-714. PubMed ID: 28294642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.